Enzo Biochem
527 Madison Ave.
New York
New York
11735-4710
United States
Tel: 212-583-0100
Fax: 212-583-0150
Website: http://www.enzo.com/
Email: info@corp.enzobio.com
364 articles about Enzo Biochem
-
New York State Health Department Approves Hepatitis B Virus Quantitative Clinical Assay
9/24/2019
Enzo Biochem, Inc. (NYSE: ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc. has received New York State approval for its AmpiProbe® HBV viral load monitoring assay for Hepatitis B virus (HBV) based on the Enzo assay’s performance versus an FDA-approved comparator product.
-
Harbert Discovery Fund Nominates Two Highly-Qualified Independent Candidates to Enzo Biochem Board
9/17/2019
Sends Letter to Shareholders Highlighting Enzo’s Sustained History of Underperformance and Missteps of Current Entrenched Board and Management Team
-
Enzo Biochem, Inc. Announces Issuance of United States Patent for Advanced Nucleic Acid Hybridization Probe Technology for Clinical and Research Applications
8/5/2019
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today announced the issuance of U.S. Patent No. 10,323,272 entitled Nucleic Acid Probes for In Situ Hybridization.
-
Enzo Biochem Announces Key Transformative Initiatives to Propel and Accelerate Growth In its Lab Business
7/11/2019
New York State Health Department Approval of Oral and Rectal STI Testing
-
Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
6/10/2019
Enzo Biochem, Inc. (NYSE:ENZ), an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics products, today reported results for the fiscal quarter and nine months ended April 30, 2019.
-
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2019 Results Tuesday, June 11, 2019 at 8:30 AM E.T.
6/5/2019
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 1870919
-
Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
5/10/2019
Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod.
-
Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals
3/11/2019
Enzo Biochem, Inc. reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
-
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.
3/5/2019
Enzo Biochem, Inc. will hold a conference call to discuss fiscal 2019 second quarter results Tuesday, March 12, 2019, at 8:30 AM E.T.
-
Enzo Biochem Reports Fiscal 2019 First Quarter Results
12/10/2018
Recent Reimbursement Cuts Emphasize Value of Enzo’s Strategy
-
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
12/6/2018
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024
-
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
12/3/2018
Enzo Biochem (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line.
-
Enzo Biochem Reports Fourth Quarter and Fiscal 2018 Results
10/15/2018
Molecular Assay Approvals from New York State Department of Health and Planned Acquisition of New Facility Highlight Progress Advancing Growth Strategy
-
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal 2018 Results Tuesday, October 16, 2018 at 8:30 AM E.T.
10/11/2018
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 fourth quarter and year end results Tuesday, October 16, 2018, at 8:30 AM E.T.
-
Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy
8/27/2018
Facility Will Enhance Enzo’s Ability to Produce and Distribute Its Growing Portfolio of Molecular Assays, Immunohistochemistry, Immunoassays and Immuno-oncology Products and Services
-
Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers and Their Progression, Especially in Women’s Health Area
7/18/2018
These cost effective, high quality primary antibodies function with our full open system workflow and complement Enzo’s strategy of introducing lower cost testing solutions for the clinical laboratory market.
-
Enzo Biochem Reports Third Quarter Ended April 30, 2018 Results
6/11/2018
Enzo Biochem Inc. reported results for the third fiscal quarter and nine months ended April 30, 2018
-
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 at 8:30 AM E.T.
6/6/2018
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 third quarter results Tuesday, June 12, 2018, at 8:30 AM E.T.
-
Enzo Biochem Reports Second Quarter and First Half Results
3/12/2018
Enzo Biochem (NYSE:ENZ) today announced results for the fiscal quarter and six months ended January 31, 2018.
-
Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test
1/22/2018
Enzo Biochem (NYSE:ENZ), an integrated diagnostics company, announced today validation of a cervical cancer biomarker detection test that provides a highly robust and cost-efficient solution for anatomical pathology.